Parathyroid hormone (1-34) counteracts the suppression of interleukin-11 expression by glucocorticoid in murine osteoblasts: A possible mechanism for stimulating osteoblast differentiation against glucocorticoid excess

Endocrinology

Volumn 154, Issue 3, 2013, Pages 1156-1167

  Kuriwaka Kido, Rika ^a   Kido, Shinsuke ^a,b   Miyatani, Yuka ^a   Ito, Yuji ^a   Kondo, Takeshi ^a   Omatsu, Takashi ^a   Dong, Bingzi ^a   Endo, Itsuro ^a   Miyamoto, Ken Ichi ^b   Matsumoto, Toshio ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DICKKOPF 1 PROTEIN; GLUCOCORTICOID; INTERLEUKIN 11; PARATHYROID HORMONE[1-34]; PROTEIN KINASE C DELTA; SMAD1 PROTEIN;

APOPTOSIS; ARTICLE; CELL DEATH; CELL DIFFERENTIATION; CONTROLLED STUDY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; OSSIFICATION; OSTEOBLAST; PHOSPHORYLATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; WNT SIGNALING PATHWAY;

ALKALINE PHOSPHATASE; ANIMALS; APOPTOSIS; CELL DIFFERENTIATION; CELLS, CULTURED; DEXAMETHASONE; GENE EXPRESSION REGULATION; INTERLEUKIN-11; MICE; OSTEOBLASTS; OSTEOCALCIN; OSTEOPROTEGERIN; PARATHYROID HORMONE; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; PROTEIN KINASE C-DELTA; PROTO-ONCOGENE PROTEINS C-FOS; PROTO-ONCOGENE PROTEINS C-JUN; RANK LIGAND; RECEPTORS, GLUCOCORTICOID; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SMAD1 PROTEIN;

EID: 84874617745     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1915     Document Type: Article

References (32)

1. Dalle Carbonare L, Arlot ME, Chavassieux PM, Roux JP, Portero NR, Meunier PJ. Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J Bone Miner Res. 2001;16:97-103.
2. Canalis E. Mechanisms of glucocorticoid action in bone. Curr Osteoporos Rep. 2005;3:98-102.
3. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest. 1998;102:274-282.
4. Kawashima I, Ohsumi J, Mita-Honjo K, et al. Molecular cloning of cDNA encoding adipogenesis inhibitory factor and identity with interleukin-11. FEBS Lett. 1991;283:199-202.
5. Keller DC, Du XX, Srour EF, Hoffman R, Williams DA. Interleukin-11 inhibits adipogenesis and stimulates myelopoiesis in human long-term marrow cultures. Blood. 1993;82:1428-1435.
6. Kodama Y, Takeuchi Y, Suzawa M, et al. Reduced expression of interleukin-11 in bone marrow stromal cells of senescence-accelerated mice (SAMP6): Relationship to osteopenia with enhanced adipogenesis. J Bone Miner Res. 1998;13:1370-1377.
7. Kido S, Kuriwaka-Kido R, Imamura T, Ito Y, Inoue D, Matsumoto T. Mechanical stress induces Interleukin-11 expression to stimulate osteoblast differentiation. Bone. 2009;45:1125-1132.
8. Inoue D, Kido S, Matsumoto T. Transcriptional induction of FosB/ δFosB gene by mechanical stress in osteoblasts. J Biol Chem. 2004; 279:49795-49803.
9. Kido S, Kuriwaka-Kido R, Umino-Miyatani Y, et al. Mechanical stress activates Smad pathway through PKCβ to enhance interleukin-11 gene transcription in osteoblasts. PLoS ONE. 2010;5: E13090.
10. Girasole G, Passeri G, Jilka RL, Manolagas SC. Interleukin-11: A new cytokine critical for osteoclast development. J Clin Invest. 1994;93:1516-1524.
11. Takeuchi Y, Watanabe S, Ishii G, et al. Interleukin-11 as a stimulatory factor for bone formation prevents bone loss with advancing age in mice. J Biol Chem. 2002;277:49011-49018.
12. Price JS, Sugiyama T, Galea GL, Meakin LB, Sunters A, Lanyon LE. Role of endocrine and paracrine factors in the adaptation of bone to mechanical loading. Curr Osteoporos Rep. 2011;9:76-82.
13. Weinstein RS, Jilka RL, Almeida M, Roberson PK, Manolagas SC. Intermittent parathyroid hormone administration counteracts the adverse effects of glucocorticoids on osteoblast and osteocyte viability, bone formation, and strength in mice. Endocrinology. 2010; 151:2641-2649.
14. Jilka RL, O'Brien CA, Ali AA, Roberson PK, Weinstein RS, Manolagas SC. Intermittent PTH stimulates periosteal bone formation by actions on post-mitotic preosteoblasts. Bone. 2009;44:275-286.
15. Kovacs CS, Chafe LL, Fudge NJ, Friel JK, Manley NR. PTH regulates fetal blood calcium and skeletal mineralization independently of PTHrP. Endocrinology. 2001;142:4983-4993.
16. Takahashi A, Ohtani N, Yamakoshi K, et al. Mitogenic signalling and the p16INK4a-Rb pathway cooperate to enforce irreversible cellular senescence. Nat Cell Biol. 2006;8:1291-1297.
17. Kim GS, Kim CH, Choi CS, Park JY, Lee KU. Involvement of different second messengers in parathyroid hormone-and interleukin-1-induced interleukin-6 and interleukin-11 production in human bone marrow stromal cells. J Bone Miner Res. 1997;12:896-902.
18. Koe RC, Clohisy JC, Tyson DR, Pulumati MR, Cook TF, Partridge NC. Parathyroid hormone versus phorbol ester stimulation of activator protein-1 gene family members in rat osteosarcoma cells. Calcif Tissue Int. 1997;61:52-58.
19. Kim CH, Cheng SL, Kim GS. Effects of dexamethasone on proliferation, activity, and cytokine secretion of normal human bone marrow stromal cells: Possible mechanisms of glucocorticoid-induced bone loss. J Endocrinol. 1999;162:371-379.
20. Hofbauer LC, Gori F, Riggs BL, et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: Potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology. 1999;140:4382-4389.
21. Lane NE, Sanchez S, ModinGW,Genant HK, Pierini E, Arnaud CD. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: Results of a randomized controlled clinical trial. J Bone Miner Res. 2000;15:944-951.
22. Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007;357: 2028-2039.
23. Saag KG, Zanchetta JR, Devogelaer JP, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: Thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009;60:3346-3355.
24. Rauch A, Seitz S, Baschant U, et al. Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor. Cell Metab. 2010;11:517-531.
25. Greenfield EM, Gornik SA, Horowitz MC, Donahue HJ, Shaw SM. Regulation of cytokine expression in osteoblasts by parathyroid hormone: Rapid stimulation of interleukin-6 and leukemia inhibitory factor mRNA. J Bone Miner Res. 1993;8:1163-1171.
26. Pollock JH, Blaha MJ, Lavish SA, Stevenson S, Greenfield EM. In vivo demonstration that parathyroid hormone and parathyroid hormone-related protein stimulate expression by osteoblasts of interleukin-6 and leukemia inhibitory factor. J Bone Miner Res. 1996; 11:754-759.
27. Sims NA, Jenkins BJ, Nakamura A, et al. Interleukin-11 receptor signaling is required for normal bone remodeling. J Bone Miner Res. 2005;20:1093-1102.
28. Bozec A, Bakiri L, Hoebertz A, et al. Osteoclast size is controlled by Fra-2 through LIF/LIF-receptor signalling and hypoxia. Nature. 2008;454:221-225.
29. Walker EC, McGregor NE, Poulton IJ, et al. OncostatinMpromotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice. J Clin Invest. 2010; 120:582-592.
30. Poli V, Balena R, Fattori E, et al. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J. 1994;13:1189-1196.
31. Kitamura H, Kawata H, Takahashi F, Higuchi Y, Furuichi T, Ohkawa H. Bone marrow neutrophilia and suppressed bone turnover in human interleukin-6 transgenic mice. A cellular relationship among hematopoietic cells, osteoblasts, and osteoclasts mediated by stromal cells in bone marrow. Am J Pathol. 1995;147:1682-1692.
32. De Benedetti F, Rucci N, Del Fattore A, et al. Impaired skeletal development in interleukin-6-transgenic mice: A model for the impact of chronic inflammation on the growing skeletal system. Arthritis Rheum. 2006;54:3551-3563.